Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | ABCC9 | O60706 | 3/20 | 0.38 |
| ▸ | ABCC8 | Q09428 | 3/20 | 0.38 |
| ▸ | KCNJ11 | Q14654 | 3/20 | 0.38 |
| ▸ | KCNJ8 | Q15842 | 3/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27173391 | 0.95 | TLR4 (0.39) | CYP17A1CYP3A4CYP11B2ABCC9ABCC8 | |
| SCHEMBL17202422 | 0.82 | TRPV4 (0.41) | CYP11B2ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL512127 | 0.81 | TLR4 (0.34) | CYP17A1CYP3A4CYP11B2ABCC9ABCC8 | |
| SCHEMBL30894019 | 0.80 | SLC6A2 (0.41) | ABCC9ABCC8KCNJ11KCNJ8SLC6A2 | |
| SCHEMBL19993904 | 0.80 | PGR (0.40) | ABCC9ABCC8KCNJ11KCNJ8SLC6A2 | |
| SCHEMBL1138835 | 0.80 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3SIRT2 | |
| SCHEMBL1138212 | 0.80 | SLC6A2 (0.41) | ABCC9ABCC8KCNJ11KCNJ8SLC6A2 | |
| SCHEMBL19993842 | 0.80 | SLC6A2 (0.40) | ABCC9ABCC8KCNJ11KCNJ8SLC6A2 | |
| SCHEMBL361341 | 0.79 | LMNA (0.43) | CYP17A1CYP3A4CYP11B2SLC6A2SLC6A4 | |
| SCHEMBL21451930 | 0.78 | KDM1A (0.48) | CYP11B2HTR2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2459197-B1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| CN-103328451-B | Compounds for the reduction of beta-amyloid production | BRISTOL MYERS SQUIBB CO | 2015-06-10 | — | — | CN | disclosed |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-06-04 | — | — | US | disclosed |
| US-8710061-B2 | Compounds for the reduction of β-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| US-8637525-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2668168-A1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8486952-B2 | Compounds for the reduction of β-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130178462-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130030011-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| WO-2012103297-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-02 | — | — | WO | disclosed |
| EP-2459197-A1 | COMPOUNDS FOR THE REDUCTION OF -AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| WO-2011014535-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | CYP17A1 1562/4885CYP3A4 2737/4885CYP11B2 200/4885 |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | CYP17A1 1562/4885CYP3A4 2737/4885CYP11B2 200/4885 |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | CYP17A1 1562/4885CYP3A4 2737/4885CYP11B2 200/4885 |
| US-20130178462-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | CYP17A1 1562/4885CYP3A4 2737/4885CYP11B2 200/4885 |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | CYP17A1 1562/4885CYP3A4 2737/4885CYP11B2 200/4885 |
| US-20130030011-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | CYP17A1 1562/4885CYP3A4 2737/4885CYP11B2 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.